Question 1

Can you advertise medicinal cannabis in Australia?

Accepted Answer

Medicinal cannabis advertising in Australia is heavily restricted under the TGA framework and AHPRA National Law. Schedule 8 products cannot be promoted directly to consumers. Marketing must use unbranded strategies, educational content, and B2B prescriber outreach that comply with TGO 93 and AHPRA advertising guidelines to avoid significant financial penalties.

Question 2

What is TGO 93 and how does it affect medicinal cannabis marketing?

Accepted Answer

TGO 93 (Therapeutic Goods Order No. 93) is the TGA's standard governing prescription medicine information. It restricts how Schedule 8 medicines, including medicinal cannabis, can be promoted. Direct-to-consumer advertising of prescription medications is prohibited. Compliant marketing must avoid efficacy or benefit claims entirely and focus on unbranded patient education or approved B2B prescriber communication.

Question 3

What is a medicinal cannabis marketing agency?

Accepted Answer

A medicinal cannabis marketing agency is a specialist firm that develops marketing strategies for cannabis clinics, cultivators, and brands within Australia's regulated framework. Unlike general agencies, a specialist firm understands TGA compliance, AHPRA advertising rules, Schedule 8 promotion restrictions, and how to build patient acquisition and prescriber outreach systems that scale without regulatory risk.

Question 4

How can medicinal cannabis clinics acquire patients legally in Australia?

Accepted Answer

Medicinal cannabis clinics in Australia can legally acquire patients through unbranded, condition-focused content marketing that educates patients on treatment options without directly promoting specific products. High-intent SEO targeting condition-based search terms, compliant landing pages, and referral-based funnels are the primary legal channels. All patient-facing content must avoid claims that breach AHPRA or TGA guidelines.

Question 5

What are AHPRA's advertising rules for healthcare?

Accepted Answer

AHPRA prohibits testimonials that create unreasonable expectations, claims of guaranteed outcomes, misleading comparisons, and use of specialist titles without appropriate registration. For medicinal cannabis marketing, AHPRA compliance is critical — breaches can result in significant fines, registration conditions, or public regulatory findings against the practitioner or business.

Question 6

Does SEKHN work with international brands entering the Australian cannabis market?

Accepted Answer

Yes. SEKHN provides Australian market entry strategy for international medicinal cannabis and healthcare brands, covering regulatory navigation, brand restructuring for the Australian context, and compliant growth architecture. Australia's medicinal cannabis market requires specific compliance knowledge that most international agencies do not possess.

Contact

Get in touch with our team today by filling in the form below or emailing us at info@sekhn.com

Contact us